Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Furthermore, there was an increase in the time taken to reach the nadir for the IR+volasertib group compared to IR alone, although this did not reach statistical significance ( Figure 6 B).

also in 111,027 other papers